Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
just got up after a night of heavy drinking and what a nice surprise DPDW had with that seemingly simple yet great news. i have said it before and will say it again, forget about a rocketship, lets just keep this train chugging uphill.
May 16, 2006
"Aurus Provides Technical Data on Its Klyon "Maple" Property and Its 1.9M Ounces of Gold and 4.9 Ounces of Silver
Today Market Value of 1.9 Million Ounces of Gold and 4.9 Million Ounces of Silver Is Approximately: USD $1,350,000,000"
i was a shareholder when that PR was release, were you?
"Aurus Yields Immediate Returns From the Krong Acquisition and Projects Revenues to Reach USD $700 Million Annually Within Three Years"
Oct 11, 2006
and to think that people are still falling for this contrivance
2create
kind of sounds like you are talking about a SCAM company and not a legit company.
Park City Group Integrates Fresh Market Manager and ActionManager(TM) Products for International Retailer
Leading Multinational Supermarket Retailer to Utilize Park City Group’s FMM and AM Products to Optimize Operations and Freshness for Consumers
Park City Group, Inc. (OTCBB: PCYG), a leading provider of inventory and labor optimization solutions, today announced that a leading international retailer has begun integrating its Fresh Market Manager and ActionManager products to optimize assortment plans, labor and task schedules, manage shrink and stock-outs, and improve quality and freshness for consumers. While numerous convenience stores have integrated Park City Group’s primary products to improve their operations, this is the first time that a supermarket retailer has done so.
The integration of these two suites allows retailers to plan production and have the correct labor plan to insure product freshness thereby maximizing sales and profits from their perishable departments. This system provides a coordinated planning of resources to deliver consumers the right product, at the right price, at the right time. The combined effort marks the completion of the first truly end-to-end Fresh Item Management system in existence delivering capabilities for category management, production planning, forecasting, promotion and pricing optimization, perpetual inventory management, computer aided ordering, work flow and labor scheduling, paperless documentation and more.
Fresh Market Manager is a fully integrated management solution for bakery, deli, food service, meat, seafood, frozen, floral and produce departments. The product helps grocers to achieve improved economic performance by managing shrink (or waste) and stock-outs. FMM also involves suppliers through Supply Chain Profit Link to deliver sales data to both sides facilitating fact-based and profit-focused category review meetings.
Together with its ActionManager solutions, Park City Group delivers one of the most robust integrated business solutions available in the industry. The systems address operations management tasks including: item level category management, inventory and production planning, work flow, scheduling, forecasting, supply and ingredient ordering, producing sales reports/projections, administering skill tests, interviewing assistance, and assessing employee knowledge.
Speaking of the agreement, Randall K. Fields, Park City Group’s Chairman and Chief Executive, said, “Inventory and labor management are the two key controllables for optimizing profit in large, sophisticated supermarket operations. This particular customer has already seen phenomenal results from our Fresh Market Manager product. The integration of both of our primary product suites will yield results far beyond what we have already witnessed when either FMM or ActionManager are installed individually.”
also another day of more buying than selling. i will once again say that we are building a solid base of investors/traders at this level who are not going to sell until DPDW is at a much higher PPS. Sooner than later the MMs are going to need shares and they will have to run it to get them.
that statement is as much fact as saying that neither of those will ever occur. the nonsense continues.
if you believe that then you have to ask yourself. why would anyone short this stock when it can be bought now and flipped for an easy 400% profit. hmmmm....
looks like we are going to have another nice day today. the recovery has begun, imo. for the second day in a row it appears the MMs are scooping up shares while raising the PPS.
reliable sources?
what a joke, the company is not even a 'reliable source'
per SLJB themselves on 1-10-07:
"Investors should not rely on any statements purporting to be by or on behalf of the Company other than those contained in this release or any future press releases issued by the Company."
can anyone get into the cams this morning? i receive a 'fail, no smart guard' error. i was hoping to watch the progress on cam 3 again. i watched all day yesterday, helps pass time at work :)
dont start with that 'short' nonsense. it is old and no one around here is short, just face reality.
"you have to be an idiot."
that is the second time you have made a personal attack by calling someone an idiot. mods, what is up here?
if you own the stock and are willing to take the risk fine. if you are pumping the BS then i have a problem. i have made my position here very clear many times.
audited financials have not been verified by anyone (such as the SEC) and the video proves absolutely nothing.
pbr, what proof do you have that AURC is real? none of their PRs have come to fruition or can be substantiated. on the pink sheets the burden of proof is on AURC and so far they have not proved anything.
its almost funny when the current PPS is lower then both the bid and ask. i think the MMs made a last ditch effort to get sellers, with little success.
Sunwin Stevia International Completes Initial Shipments of OnlySweet(TM) to Major Grocery Outlets in the United States
OnlySweet(TM) Anticipated to Be Carried in Over 30 States in July
Sunwin Stevia International Corp., a wholly owned subsidiary of Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), announced today that its OnlySweet(TM) line of products are now available for purchase at a wide variety of national grocery chains throughout the United States as the Company has completed its initial shipments. OnlySweet(TM) is a proprietary product line blended with Stevioside (stevia), a natural sweetener, extracted from the leaves of the Stevia rebaudiana plant. OnlySweet(TM) is blended in an FDA approved facility in the United States that provides similar services to some of the most highly recognized brands in the food industry. In addition, the company received Kosher certification in June of 2007.
In 2006, it was announced that Sunwin Stevia International Corp. had developed its OnlySweet(TM) line of products using its proprietary blend of stevia, formulated through extensive research and testing for consistency and flavor. The Company launched its website www.onlysweet.com, offering OnlySweet(TM) to the public in January 2007.
Now that initial shipments have been delivered, OnlySweet(TM) is available for purchase in several national grocery chains and will soon be available in over 30 states. The company's first order came from one of the largest grocery retailers in the United States, for distribution in their stores on a national rollout. The company has received numerous additional orders from other regional chains as Sunwin Stevia International Corp. continues to aggressively market the OnlySweet(TM) line of products and the Company expects additional outlets will be carrying the product throughout the year.
Working in concert with retailers and in response to their input, the Company has recently redesigned its packaging to highlight the "All Natural" attributes of OnlySweet(TM). The Company and retailers believe the significant up-trend in the purchase of "All Natural" products will further differentiate OnlySweet(TM) from its competition and lead to increased sales.
there is a pattern here, ironic that so many people follow someone with such a bad track record (great to trade, but horrible to hold long)
there have also been 3 to 5 welders working on cam 4 all day. this is the most action we have had on the cams since they were re-launched.
bazooka, search for DPDW quote/chart/ticket in the upper left box and then go to historical.
104,000
DPDW is working on a project of some sort on cam 3 today. the parts appear to be legs or braces of some sort.
fasteddie777, i did :)
VITA - "Orthovita in Conjunction with Canaccord Adams will Conduct an Institutional Investors Meeting on Thursday, June 14th, in Chicago
Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, announced today that it will conduct an institutional investor meeting in conjunction with Canaccord Adams, Inc. on Thursday, June 14th, 2007 in Chicago, IL. Antony Koblish, president and chief executive officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 1:00 p.m. to 5:00 p.m. Central Time, in the Washington Room of The Sears Tower, 233 South Wacker Drive, Chicago, IL. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting.
In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 2:00 p.m. and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Dr. Hatten is one of the 19 clinical sites involved in the FDA Investigational Device Exemption (IDE) study and will cover part of a prospective randomized controlled study being conducted under an FDA IDE study. At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement."
"Orthovita in Conjunction with Canaccord Adams will Conduct an Institutional Investors Meeting on Thursday, June 14th, in Chicago
Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, announced today that it will conduct an institutional investor meeting in conjunction with Canaccord Adams, Inc. on Thursday, June 14th, 2007 in Chicago, IL. Antony Koblish, president and chief executive officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 1:00 p.m. to 5:00 p.m. Central Time, in the Washington Room of The Sears Tower, 233 South Wacker Drive, Chicago, IL. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting.
In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 2:00 p.m. and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Dr. Hatten is one of the 19 clinical sites involved in the FDA Investigational Device Exemption (IDE) study and will cover part of a prospective randomized controlled study being conducted under an FDA IDE study. At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement."
christoph, AURC has not delivered on a single PR they have EVER issued. open zee eyes.
cargill is trying to have stevia 'upgraded' from a dietary supplement to a food additive. per last weeks PR:
"Under terms of the new partnership, Cargill is handling product development and the regulatory approval process for the ingredient, including working on clinical trials to support a food additive petition"
http://www.naturalproductsinsider.com/hotnews/76h1153042.html
.55 x .58
that is just what we needed. now that NITE has quit selling we should be heading up.
airys, what happened to the financial numbers that SLJB posted on their website last year?
VITA - Orthovita Announces Podium Presentation of CORTOSS(R) for the Treatment of Vertebral Compression Fractures - Vertebral Augmentation to be Presented at the American Society of Neuroradiology (ASNR) Meeting in Chicago
Prospective Randomized Pivotal Trial of CORTOSS versus PMMA In the Treatment of Vertebral Compression Fractures;
Preliminary Results at a Single Institution in 57 Patients
Orthovita, Inc. (NASDAQ: VITA), a spine and biosurgery company, reported that H. Paul Hatten, Jr., M.D., from Vero Beach, Florida, will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at the American Society of Neuroradiology (ASNR) meeting being held in Chicago, IL on Thursday June 14, 2007.
The podium presentation is on Thursday June 14, at 11:43 a.m. in Room Columbus I-L of the Hyatt Regency and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Patients are evaluated at pre-op, post-op, 72 hours, 1 week, 1, 3, 6, 12, and 24 months. Patient outcomes are assessed over time with the use of the Visual Analogue pain Scale (VAS), the Oswestry Disability Index (ODI), and the SF-12. Furthermore, maintenance of height and alignment of the level(s) treated are also monitored over time. Among the inclusion criteria are a minimum VAS pain score of 50/100, a minimum ODI score of 30% caused by recent (an) osteoporotic compression fracture(s) at one or two levels as evidenced by the presence of edema on MRI or bone scan. Exclusion criteria include greater than 70% vertebral collapse, spinal canal compromise, neurologic deficit at the level (s) to be treated, or tumors. Post-operative CT and radiographs are used to assess and quantify leakage. The results reported on this week were collected by Dr. Hatten at Indian River Radiology of Vero Beach, Florida, one of the 19 clinical sites involved in this IDE study.
At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement. The most striking difference between CORTOSS and PMMA seen in this subset of the larger IDE study is that the average volume of material injected per vertebra was 1.17 cc for CORTOSS and 2.41 cc for PMMA treated group.
“These preliminary results suggest that CORTOSS may provide similar pain relief compared to PMMA bone cement with approximately 50% less material,” said Dr. Hatten. “This may be due to the distinct interdigitated trabecular fill pattern obtained with CORTOSS, as opposed to the more homogenous “ball-like” fill seen with PMMA. This difference in fill pattern has the potential to reduce the risk of leakage. Early laboratory investigations also indicate that this fill pattern in combination with CORTOSS’ strength may result in a more favorable biomechanical environment.”
There are an estimated 700,000 osteoporotic vertebral compression fractures in the United States each year. Orthovita believes that the CORTOSS clinical study is the most rigorous trial ever enrolled for vertebral compression fractures of the spine. The prospective, randomized study protocol was developed in accordance with the FDA’s vertebral compression fracture guidance document.
CORTOSS has CE Certification for use in the European Union for screw augmentation and for vertebral augmentation. This enables CORTOSS to be sold in the European Union as well as in other countries that have adopted the European Union’s regulatory standards. CORTOSS is not available for sale in the United States and is limited to investigational use.
About the Company
Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL® Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS® Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash Corporation to develop and commercialize synthetic-based biomaterial products, we market VITAGEL under a license granted by Angiotech Pharmaceuticals, Inc., and we continue to pursue similar relationships with other biomaterials companies.
"Orthovita Announces Podium Presentation of CORTOSS(R) for the Treatment of Vertebral Compression Fractures - Vertebral Augmentation to be Presented at the American Society of Neuroradiology (ASNR) Meeting in Chicago"
"Prospective Randomized Pivotal Trial of CORTOSS versus PMMA In the Treatment of Vertebral Compression Fractures;
Preliminary Results at a Single Institution in 57 Patients
Orthovita, Inc. (NASDAQ: VITA), a spine and biosurgery company, reported that H. Paul Hatten, Jr., M.D., from Vero Beach, Florida, will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at the American Society of Neuroradiology (ASNR) meeting being held in Chicago, IL on Thursday June 14, 2007.
The podium presentation is on Thursday June 14, at 11:43 a.m. in Room Columbus I-L of the Hyatt Regency and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Patients are evaluated at pre-op, post-op, 72 hours, 1 week, 1, 3, 6, 12, and 24 months. Patient outcomes are assessed over time with the use of the Visual Analogue pain Scale (VAS), the Oswestry Disability Index (ODI), and the SF-12. Furthermore, maintenance of height and alignment of the level(s) treated are also monitored over time. Among the inclusion criteria are a minimum VAS pain score of 50/100, a minimum ODI score of 30% caused by recent (an) osteoporotic compression fracture(s) at one or two levels as evidenced by the presence of edema on MRI or bone scan. Exclusion criteria include greater than 70% vertebral collapse, spinal canal compromise, neurologic deficit at the level (s) to be treated, or tumors. Post-operative CT and radiographs are used to assess and quantify leakage. The results reported on this week were collected by Dr. Hatten at Indian River Radiology of Vero Beach, Florida, one of the 19 clinical sites involved in this IDE study.
At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement. The most striking difference between CORTOSS and PMMA seen in this subset of the larger IDE study is that the average volume of material injected per vertebra was 1.17 cc for CORTOSS and 2.41 cc for PMMA treated group.
“These preliminary results suggest that CORTOSS may provide similar pain relief compared to PMMA bone cement with approximately 50% less material,” said Dr. Hatten. “This may be due to the distinct interdigitated trabecular fill pattern obtained with CORTOSS, as opposed to the more homogenous “ball-like” fill seen with PMMA. This difference in fill pattern has the potential to reduce the risk of leakage. Early laboratory investigations also indicate that this fill pattern in combination with CORTOSS’ strength may result in a more favorable biomechanical environment.”
There are an estimated 700,000 osteoporotic vertebral compression fractures in the United States each year. Orthovita believes that the CORTOSS clinical study is the most rigorous trial ever enrolled for vertebral compression fractures of the spine. The prospective, randomized study protocol was developed in accordance with the FDA’s vertebral compression fracture guidance document.
CORTOSS has CE Certification for use in the European Union for screw augmentation and for vertebral augmentation. This enables CORTOSS to be sold in the European Union as well as in other countries that have adopted the European Union’s regulatory standards. CORTOSS is not available for sale in the United States and is limited to investigational use."
hockmir,
how can you continue to support SLJB when you have been around since before reality hit and the sky fell?
hockmir, the source was SJLB on their site before they pulled the information. wonder why? probably because it was BS just like everything else they have stated.
nm - delete
random connections
Nexen and BHP are both DPDW clients ( http://www.deepdowninc.com/pages/extranet.htm )
Eugene Butler, the new DPDW CFO used to run Weatherford.
search google for nexen bhp weatherford and you will find these companies have done business together for years and co-own oil 'blocks'
i will tell you how a stock is shorted by accident...it happened to me.
i opened a new td ameritrade apex account because i was still using an older ameritrade account with different features. i placed a sell order the day that tdameritrade moved my funds to my new account. the sell order went through however tdameritrade screwed up and ended up shorting that stock. do not ask me how they did it but i had to call them to have it corrected.
just click on whatever camera you want to control. when you do it is oulined in green and is the active camera for the controls. double click any camera and that is the solitary image in the window. you can also double click the webguard logo to control the camera stats such as time and DVR info. zoom, exposure, aperture etc are also functioning.
the company that provides the software and much of the hardward for this system is IDIS
http://www.idis.co.kr/eng/
camera 1 is not the only camera that can be controlled. most of the camersas are 100% controllable and only a few, such as 5,6 and 7 are locked down. looking at the birds eye view of the facility we are unable to see the majority of the warehouse interior and i have a feeling that is where much of the inventory is. there are also a lot of vehicles there during the day but few of those people work in an area visible by security cam. imo there is a lot of DPDW 'action' that we are unable to see with these cams.
because i was invested in AURC for over a year and am going to follow this till the end. if i can prevent some innocent people from being scammed in the process than great.
every AURC post i have made has been reality and nothing i have said has been incorrect. i do not post one line useless posts like many here do, including you. i have clearly and honestly stated my position around here and that has not changed. you can keep up the 'hedge fund' and 'shorty' nonsense but it remains just that, nonsense. maybe you could learn from those who are older and wiser then yourself.